Q-omics provides the consensus-scored PPIAL4A profile across patient tissues and cancer cell-line models. PPIAL4A expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, PPIAL4A is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, PPIAL4A RNA expression shows 7,970 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LUAD, COAD, and TGCT as cancer lineages where PPIAL4A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPIAL4A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPIAL4A survival associations across molecular data types. PPIAL4A RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPIAL4A RNA expression–survival associations across cancer types. High PPIAL4A expression shows unfavorable associations in LUAD and LGG, but favorable associations in SCLC, READ, CHOL and ACC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for PPIAL4A RNA expression.
This table summarizes PPIAL4A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in UCEC for RNA.
This table ranks reproducible tumor–normal expression differences for PPIAL4A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPIAL4A shows higher tumor expression in COAD, UCEC, BLCA, HNSC, BRCA and LUAD. The COAD box plot shows higher PPIAL4A RNA expression in tumor versus normal tissue (log2 FC = +0.225, t-test p < 0.001).
This table shows molecular features associated with PPIAL4A in patient tissues and cancer cell lines. In patient samples, PPIAL4A shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, PPIAL4A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Lymphoma.
